Mineralocorticoid antagonism: a novel way to treat sarcopenia and physical impairment in older people?

    Research output: Contribution to journalReview article

    20 Citations (Scopus)

    Abstract

    Dysregulation of the renin-angiotensin-aldosterone system has been associated with a number of age-related pathologies including hypertension, heart failure and chronic kidney disease. More recently, it has been suggested that alterations within the RAAS may contribute to the development of sarcopenia and subsequent decline in physical function. There is growing interest in developing interventions to prevent age-associated decline in muscle function. We postulate that inhibition of the RAAS with the mineralocorticoid antagonist spironolactone may have a role in countering the effects of physical impairment in older people by improving skeletal muscle function. Spironolactone may prevent skeletal myocyte apoptosis, improve vascular endothelial function and enhance muscle contractility by increasing muscle magnesium and sodium-potassium pumps. This article will review the literature underpinning the hypothesis that spironolactone may have a role in maintaining muscle function in older people.

    Original languageEnglish
    Pages (from-to)725-729
    Number of pages5
    JournalClinical Endocrinology
    Volume75
    Issue number6
    DOIs
    Publication statusPublished - Dec 2011

    Keywords

    • CONGESTIVE-HEART-FAILURE
    • CONVERTING ENZYME-INHIBITION
    • LEFT-VENTRICULAR DYSFUNCTION
    • NECROSIS-FACTOR-ALPHA
    • SKELETAL-MUSCLE
    • NITRIC-OXIDE
    • ENDOTHELIAL FUNCTION
    • EXERCISE TOLERANCE
    • MYOCYTE APOPTOSIS
    • CONTROLLED-TRIAL

    Cite this